Description

MECHANISM: SMA pathology is driven by a homozygous loss-of-function of SMN1, leaving SMN2 as the sole source of SMN protein. A C•G-to-T•A transition at position +6 of SMN2 exon 7 disrupts an exonic splicing enhancer (ESE) and simultaneously creates an exonic splicing silencer (ESS), causing the spliceosome to skip exon 7 in approximately 85-90% of SMN2 transcripts (PMID: 38057426). The resulting truncated SMNΔ7 protein is rapidly degraded and functionally incompetent, meaning only the minority (~10-15%) of full-length transcripts produce functional SMN protein (PMID: 37194521, PMID: 34573328). Because SMN copy number directly modifies disease severity, even modest increases in exon 7 inclusion frequency—sufficient to shift the splicing equilibrium toward full-length mRNA—can meaningfully elevate SMN protein levels and ameliorate the motor neuron degeneration that characterizes SMA. The intronic splicing silencer element ISS-N1, located within intron 7 immediately downstream of exon 7, is a critical negative regulator that can be antagonized to enforce exon inclusion, as demonstrated mechanistically for nusinersen (PMID: 41551726). Small molecules such as risdiplam and securinine act through distinct but convergent mechanisms—risdiplam stabilizes a 5' splice-site recognition complex on exon 7, while securinine's mechanism likely involves upstream splicing factor modulation—each promoting exon 7 retention (PMID: 39363429, PMID: 28152480). EVIDENCE CONVERGENCE: Multiple independent therapeutic modalities targeting the same splicing event have demonstrated efficacy, providing exceptionally strong convergent validation of the mechanism. Nusinersen, an antisense oligonucleotide targeting ISS-N1, is clinically approved and robustly increases full-length SMN2 mRNA in SMA patient fibroblasts (PMID: 41754920, PMID: 29434670, PMID: 32294764). Risdiplam, a chemically unrelated oral small molecule, achieves the same splicing outcome through RNA-binding stabilization and is also clinically approved (PMID: 41109767, PMID: 39363429). Emerging RNA-targeting platforms—including a dRfxCas13d system conjugated to a risdiplam-derived moiety—independently recapitulate exon 7 inclusion, confirming the locus is pharmacologically tractable via entirely orthogonal biochemical mechanisms (PMID: 41122778). Securinine increases exon 7 inclusion in both reporter assays and in vivo spinal cord tissue of SMA model mice (PMID: 28152480), further broadening the mechanistic footprint. Subcutaneous and intracerebroventricular delivery of nusinersen-like ASOs both restore splicing (PMID: 41683702), indicating the splicing defect is the primary therapeutic node irrespective of route of administration. CONTRADICTIONS AND LIMITATIONS: Despite robust splicing correction, clinical outcomes with nusinersen and risdiplam show variable and incomplete efficacy, particularly in patients with severe Type 1 SMA and delayed treatment onset, suggesting that SMN restoration alone may be insufficient once irreversible motor neuron loss has occurred. The current evidence base is largely derived from exon-skipping reporter assays, patient-derived fibroblasts, and mouse models that incompletely recapitulate human SMA neurodegenerative kinetics; direct quantification of SMN protein restoration thresholds required for functional rescue in human spinal motor neurons remains imprecisely defined. Additionally, the mechanism of securinine-mediated exon 7 inclusion has not been fully elucidated at the molecular level, limiting rational combination strategies. Off-target splicing effects of systemic small molecules like risdiplam across the transcriptome represent an undercharacterized safety concern that could confound long-term therapeutic benefit. THERAPEUTIC ANGLE: The mechanistic clarity of SMN2 splicing correction makes this the most validated therapeutic axis in SMA. ASOs targeting ISS-N1 (nusinersen paradigm) are optimal for CNS-localized delivery via intrathecal injection, providing durable target engagement with infrequent dosing due to long ASO half-life in neural tissue. Oral small molecules (risdiplam paradigm) offer systemic SMN restoration including in peripheral tissues and are preferable for patients where peripheral motor neuron and muscle involvement is prominent. Next-generation RNA-targeting platforms, such as Cas13d-splicing factor conjugates, offer programmable precision with potentially reduced off-target splicing modulation (PMID: 41122778). Combination of an exon-inclusion modality with neuroprotective or muscle-directed co-therapies (e.g., gene therapy for SMN1 replacement in treatment-naive severe patients) represents the most compelling near-term clinical rationale, as converging evidence indicates that SMN restoration and motor neuron survival are partially orthogonal problems in advanced disease.

Key questions

• What is the minimum fold-increase in SMN2 exon 7 inclusion frequency—and corresponding SMN protein level—required to halt motor neuron axon retraction in human iPSC-derived spinal motor neurons depleted of SMN1, as measured by longitudinal live-cell imaging and NMJ formation assays?
• Does combinatorial ISS-N1 ASO treatment plus risdiplam produce synergistic or merely additive increases in full-length SMN2 mRNA in SMA patient fibroblasts and in the Taiwanese SMA mouse model, and does this correlate with a superior survival phenotype compared to monotherapy?
• Can dRfxCas13d-risdiplam conjugate delivery via AAV9 to the CNS of neonatal SMA mice achieve exon 7 inclusion rates comparable to nusinersen with reduced off-target splicing changes across the transcriptome as quantified by long-read RNA sequencing?
• Is the securinine-mediated increase in SMN2 exon 7 inclusion dependent on modulation of hnRNP A1 or SR protein activity, and can CLIP-seq or iCLIP identify the specific splicing factor whose occupancy at the exon 7 ESS is altered by securinine treatment?
• Does the timing of splicing correction relative to disease onset (pre-symptomatic vs. post-symptomatic) differentially affect the number of rescued functional motor units in the EDL and soleus muscles of SMA model mice, as assessed by electromyography and single-fiber NMJ immunofluorescence?

Supporting evidence (215)

• 3afaef0c-16a7-b056-3c78-9b54b1640c5a
• 1c270620-1ac3-7f24-25b3-92afa3651a08
• 49b47002-ca40-3279-3439-f4c90dc5282a
• 6ad826c9-9d02-4911-afc4-c286600b7c93
• 829356ed-7b91-e896-78ad-416b6b1d1722
• 227ca296-c3fb-e53a-c54b-15fe018ed620
• 023823e0-653e-6003-c9a5-58163decdd91
• 39fdf7ef-1f82-8381-7b6a-a3777a8a0da2
• 1a17b577-a1ed-45e4-a4a8-449fa57e84b3
• 3121a1b6-912f-c32f-4772-9f416fbd9199
• a29c0c15-4c72-7ff9-db28-5f3064326933
• f999f665-70da-0da2-5a2d-ed44a37a10dd
• a49e44b7-ae7a-0d63-ded6-a89304e2a11b
• 23e4080e-ea60-4c63-b5fa-5f79c0537201
• e0d25459-64fd-413c-b6bd-c91a70a351de
• 617aa479-7cf6-4802-928f-df49370c0d89
• cce23ea7-564a-4480-958f-9c86d6967d85
• c87bdb78-9714-4a64-82f3-6a06b6989e96
• 5aaf2f28-366a-84a7-78bf-0645859240b7
• 37787f16-1498-cc39-ab68-f840f76a0e90
• … and 195 more

Related claims (20)